Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
You may also be interested in...
Aegerion’s Lomitapide Gets Standard Review For Rare Genetic Cholesterol Disease
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
Aegerion’s Lomitapide Gets Standard Review For Rare Genetic Cholesterol Disease
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
Genzyme/Isis On Track To Submit Cholesterol Drug Mipomersen In 1H 2011
Mipomersen, Genzyme/Isis Pharmaceuticals' second-generation antisense drug for severe high cholesterol, is four for four in terms of collecting positive outcomes in Phase III trials. But in addition to lowered cholesterol, patients in all of those studies had elevated liver enzymes, leaving open the question whether regulators will consider the side effect a manageable trade off for filling an unmet medical need